Hemispherx Ampligen Amendment Will Jumpstart NDA Clock

Biopharma prepares to respond to all 14 deficiencies cited in FDA’s refuse-to-file letter for the Toll-like receptor-3 agonist. Firm also exploring drug’s use as an adjuvant for HIV/AIDS and avian influenza vaccines